Nikolaidis P, Metallidis S, Katikaridou E, Chatzidimitriou M, Kollaras P, Tsona A, Koumentaki E, Tourkantonis A
First Department of Internal Medicine, Infectious Diseases Division, University Hospital AHEPA, Thessaloniki, Greece.
J Chemother. 2002 Dec;14(6):544-6. doi: 10.1179/joc.2002.14.6.544.
Staphylococcus aureus strains resistant to a variety of antimicrobial agents are often found in the hospital environment and are responsible for many life-threatening infections. The activity of quinupristin/dalfopristin against 84 Staphylococcus aureus bloodstream isolates (both methicillin resistant and methicillin sensitive) was compared to the activity of vancomycin, teicoplanin, erythromycin, oxacillin, clindamycin, gentamicin, rifampicin. The Minimum Inhibitory Concentrations of these agents was evaluated with the Epsilometer Test. Quinupristin/dalfopristin inhibited all methicillin-sensitive strains at 1mg/L, and 75% of methicillin-resistant strains at 1.5mg/L. According to these results, quinupristin-dalfopristin shows promising in-vitro activity and may be a welcome alternative treatment for methicillin-resistant staphylococcal infections, resulting in reduced use of glycopeptides.
耐多种抗菌剂的金黄色葡萄球菌菌株在医院环境中经常被发现,并且是许多危及生命感染的病原体。将奎奴普丁/达福普汀对84株金黄色葡萄球菌血流分离株(耐甲氧西林和甲氧西林敏感)的活性与万古霉素、替考拉宁、红霉素、苯唑西林、克林霉素、庆大霉素、利福平的活性进行了比较。使用Epsilometer试验评估了这些药物的最低抑菌浓度。奎奴普丁/达福普汀在1mg/L时抑制所有甲氧西林敏感菌株,在1.5mg/L时抑制75%的耐甲氧西林菌株。根据这些结果,奎奴普丁-达福普汀显示出有前景的体外活性,并且可能是耐甲氧西林葡萄球菌感染的一种受欢迎的替代治疗方法,从而减少糖肽类药物的使用。